定坤丹联合促排卵治疗多囊卵巢综合征不孕患者的疗效分析

Analysis of The Efficacy of Dingkun Pills Combined with Ovulation Stimulation in The Treatment of Infertility Patients with Polycystic Ovary Syndrome

目的探讨定坤丹联合促排卵治疗多囊卵巢综合征(PCOS)不孕患者的临床疗效。方法选择2022年1月至2022年6月在开封市妇产医院生殖医学科就诊的PCOS不孕患者67例,随机分为治疗组和对照组,治疗组37例,对照组30例。对照组采用来曲唑+尿促性素治疗,治疗组的促排卵方案同对照组,同时加用定坤丹治疗。比较两组患者的绒促性素(HCG)注射日雌二醇(E_(2))水平、排卵日子宫内膜厚度、排卵数、促排卵天数、促性腺激素(Gn)用量、阴超检测次数、周期费用、生化妊娠率、临床妊娠率、早期流产率、异位妊娠率、多胎率、卵巢过度刺激综合征发生率及安全性评价指标。结果治疗组患者HCG注射日E_(2)水平[(391.01±91.61)pg/ml vs.(324.70±87.39)pg/mL,P=0.004]和排卵日子宫内膜厚度[(12.06±1.43)mmvs.(9.51±1.30),P=0.000]均高于对照组;两组患者的排卵数[(1.46±0.56)vs.(1.30±0.53),P=0.240]无差异;治疗组患者的促排卵天数[(7.19±1.20)vs(8.20±1.24),P=0.001]、Gn用量[(391.27±92.09)Uvs(460.00±93.91)U,P=0.004]、阴超检测次数[(4.05±0.94)vs(4.83±0.95),P=0.001]均少于对照组;治疗组患者的周期费用[(1027.64±106.20)元vs(702.57±81.84)(元),P=0.000]高于对照组;治疗组患者的临床妊娠率(43.24%vs16.67%,P=0.033)高于对照组;生化妊娠率、早期流产率(2.70%vs3.33%,P=1.000;6.25%vs20.00%,P=0.429)低于对照组,但差异无统计学意义;两组患者均无异位妊娠、多胎及卵巢过度刺激综合征发生。两组患者治疗前后安全性评价指标均无异常,且比较无统计学差异。结论定坤丹联合促排卵治疗是一种安全有效的治疗方法,值得临床推广应用。

Objective To investigate the clinical efficacy of Dingkun Pills combined with ovulation stimulation in the treatment of infertility patients with polycystic ovary syndrome(PCOS).Methods Totally 67 infertile patients with PCOS in the Department of Reproductive Medicine,Kaifeng Obstetrics and Gynecology Hospital from January 2022 to June 2022 were selected and randomly divided into treatment group(n=37)and control group(n=30).The control group were treated with letrozole and human menopausal gonadotrophins,and the treatment group were treated with the same ovulation stimulation protocol as the control group,and Dingkun Pills were used at the same time.The estradiol(E_(2))level on the day of human chorionic gonadotropin(hCG)injection,endometrial thickness on the day of ovulation,ovulation number,ovulation stimulation days,gonadotropin(Gn)dosage,number of trauavaginal ultrasound examination,cycle cost,biochemical pregnancy rate,clinical pregnancy rate,earlyabortion rate,ectopic pregnancy rate,multiple pregnancy rate,ovarian hyperstimulation syndrome rate and safety were compared between the two groups.Results In the treatment group,the E_(2) level on the day of hCG injection was[(391.01±91.61)pg/ml vs.(324.70±87.39)pg/ml,P=0.004]and the endometrial thickness on the day of ovulation was[(12.06±1.43)mm vs.(9.51±1.30)].P=0.000].There was no significant difference in the number of ovulation between the two groups[(1.46±0.56)vs.(1.30±0.53),P=0.240].In the treatment group,the ovulation induction days[(7.19±1.20)vs(8.20±1.24),P=0.001],Gn dosage[(391.27±92.09)U vs(460.00±93.91)U,P=0.004],and the number of trauavaginal ultrasound examination[(4.05±0.94)vs(4.83±0.95),P=0.001]were less than those in the control group.The cycle cost of the treatment group[(1027.64±106.20)yuan]was significantly higher than that of the control group[(702.57±81.84)yuan,P=0.000].The clinical pregnancy rate of the treatment group(43.24%)was higher than that of the control group(16.67%,P=0.033).The biochemical pregnancy rate and early abortion rate(2.70%vs3.33%,P=1.000;6.25%vs20.00%,P=0.429)in the treatment group were lower than that in the control group,but the difference was not statistically significant.No ectopic pregnancy,multiple births and ovarian hyperstimulation syndrome occurred in the two groups.The safety evaluation indexes of the two groups were normal before and after treatment,and there was no statistically significant difference between the two groups.Conclusion Dingkun Pills combined with ovulation stimulation therapy is a safe and effective treatment method.It's worthy of clinical application.